Latest Healthcare News

Page 92 of 180
Opthea Limited has terminated its sozinibercept wet AMD program following Phase 3 trial failures and settled a major funding agreement, setting the stage for a strategic reset.
Ada Torres
Ada Torres
20 Aug 2025
dorsaVi Ltd has unveiled Artemis Labs, a new subsidiary focused on developing advanced AI, sensor, and robotics technologies powered by cutting-edge RRAM. This initiative aims to transform human movement data into intelligent robotic and healthcare applications.
Sophie Babbage
Sophie Babbage
20 Aug 2025
Dexus posted a 5.4% rise in revenue for FY25 but reported a substantial net loss driven by impairments, while increasing distributions to security holders.
Eva Park
Eva Park
20 Aug 2025
Centuria Capital Group has outperformed its FY25 earnings guidance, reporting a 4.3% rise in operating EPS and announcing ambitious FY26 growth targets alongside the launch of Australia’s first public sovereign AI Factory.
Eva Park
Eva Park
19 Aug 2025
Centuria Capital Group reported a robust FY25 with $19.7 billion in assets under management and earnings per stapled security exceeding guidance. The group is poised for strong FY26 growth, driven by stabilizing real estate markets and its pioneering sovereign AI Factory.
Eva Park
Eva Park
19 Aug 2025
Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.
Ada Torres
Ada Torres
19 Aug 2025
Opthea has successfully settled its Development Funding Agreement, avoiding a potential $680 million liability and securing $20 million in cash. Leadership changes include the CEO and CFO stepping down, with the Chairman assuming CEO duties.
Ada Torres
Ada Torres
19 Aug 2025
CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.
Ada Torres
Ada Torres
19 Aug 2025
CSL Limited has announced an unfranked ordinary dividend of USD 1.62 per share for the first half of 2025, with payments scheduled in multiple currencies depending on shareholder location.
Ada Torres
Ada Torres
19 Aug 2025
CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.
Ada Torres
Ada Torres
19 Aug 2025
CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.
Ada Torres
Ada Torres
19 Aug 2025
Rhythm Biosciences has launched a $3.75 million placement alongside an offer of over 52 million new options, all contingent on shareholder approval. The move aims to bolster working capital as the company advances its cancer diagnostic products.
Ada Torres
Ada Torres
18 Aug 2025